Neuro Blossom Bio symbolizes the convergence of Neuroscience, Life Science, and AI, blossoming into innovative technologies and research. The name reflects our mission to pioneer new possibilities in life sciences, beginning with therapeutics for neurodegenerative diseases and expanding to treatments for intractable conditions such as fibrosis.

Neurobbio Inc. is developing NBB-116, an oral Alzheimer’s disease candidate derived from its proprietary NeuroADMET AI platform. Supported by compound patents, NBB-116 has undergone initial animal efficacy and safety assessments, demonstrating readiness and competitiveness for preclinical advancement.